Wegovy childhood obesity trial success
Novo Nordisk Trial Shows Wegovy Reduces Obesity in Young Children
Anonymous
Key Points
1
Children in the trial received once-weekly subcutaneous semaglutide at a maximum dose of either 1.7 mg or 2.4 mg, determined by their baseline weight.
2
Ania M. Jastreboff of Yale said the results were notable because about 40% of children moved below the obesity threshold despite most participants having class II or III severe obesity at baseline.
3
Novo Nordisk said obesity prevalence is increasing among children in this age group, for whom there are limited clinically tested and approved treatments when lifestyle changes alone are insufficient.
4
The company said the trial’s primary endpoint was the percentage change in BMI from baseline at week 68, and that semaglutide produced a greater reduction than placebo.
5
Investing.com cited estimates that about 177 million children ages 5 to 19 were living with obesity in 2025, with that figure projected to rise to 228 million by 2040.
Novo Nordisk announced that its obesity drug Wegovy helped 40% of children ages 6 to 11 drop below the obesity threshold in a major trial. Contemporary Pediatrics reported that after 68 weeks of once-weekly semaglutide injections combined with diet and exercise, treated children showed significantly lower BMI than those on placebo. The company found no new safety concerns, though most participants started with severe obesity.
The trial enrolled 165 children, with more than 85% having class II or III severe obesity at baseline. Patient Care Online noted this is particularly significant because treatment options for this age group remain limited when lifestyle changes alone fall short. Detailed results are expected in November.
A Major Shift in Childhood Obesity Treatment
Children in the trial received once-weekly semaglutide injections at doses of 1.7 mg or 2.4 mg based on their starting weight. Contemporary Pediatrics explained that semaglutide, a GLP-1 receptor agonist, works by affecting hunger and blood sugar. The 68-week study showed treated children achieved much greater BMI reductions than the placebo group.
Ania M. Jastreboff of Yale called the results notable because 40% of participants moved below the obesity threshold despite starting with severe cases. Patient Care Online highlighted that childhood obesity treatments remain scarce when diet and exercise alone don't work. The trial's primary goal was measuring BMI change from baseline, and semaglutide clearly outperformed placebo.
Why This Trial Matters Now
Childhood obesity rates are climbing globally. Finance Yahoo reported that about 177 million children ages 5 to 19 were living with obesity in 2025. Without intervention, that number is projected to jump to 228 million by 2040. Novo Nordisk emphasized that this age group has very few clinically tested and approved weight-loss options.
Approved treatments for young children are extremely limited. Patient Care Online noted that when lifestyle modifications fail, families have few medical alternatives. This trial result could expand treatment access for kids struggling with severe obesity and related health risks like type 2 diabetes and heart disease.
Safety Questions Resolved, Full Data Coming
Parents and doctors naturally worry about giving weight-loss drugs to children. Contemporary Pediatrics reported that Novo Nordisk found no new safety concerns in the trial. The company specifically confirmed no issues with growth or pubertal development, addressing a major concern about drug use during critical developmental years.
The company will release full trial details in November, which could answer remaining questions about long-term effects. Finance Yahoo noted that despite the positive pediatric result, Novo Nordisk stock fell 2% after the company halted two separate heart-failure trials. Investors will likely await more complete safety and efficacy data before making major decisions.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
88
Reach
104
A
AnonymousAuthor
